Aptose Biosciences Inc (APS.TO) has seen stable price action amid recent developments.
This week, Aptose's stock remains steady, closing at C$2.40 with no change in price over the past day or week. The company has been in the spotlight recently due to its acquisition by Hanmi Pharmaceutical and its ongoing clinical trials.
Investor takeaway: Investors should remain cautious as Aptose continues to navigate its transition post-acquisition while also focusing on its clinical development programs.
Advertisement
Aptose Biosciences Inc
APS.TO
APS.TO
Aptose Biosciences Inc
WealthAwesomeMarket cap
$6.13M
52W high
$2.59
52W low
$1.41
1W change
+0.00%
Beta
0.34
Analyst Price Targets
Based on analyst covering APS
Wall Street analysts forecast APS stock price to fall 1.7% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.36
-1.7% Upside
Current Price
C$2.40
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APS's historical volatility
30-Day Vol
52.7%
Annualized
90-Day Vol
48.9%
Annualized
Trend (90d)
-0.0%
Annualized drift
90d Mean
C$2.40
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$2.40 | C$2.00 โ C$2.88 |
| 60 trading days | C$2.40 | C$1.86 โ C$3.10 |
| 90 trading days | C$2.40 | C$1.75 โ C$3.29 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Aptose's stock has remained stable at C$2.40 with a year-to-date gain of 18.81%.
With a market cap of C$6.13 million and a current price significantly within its 52-week range of C$1.41 to C$2.59, Aptose's stock performance reflects cautious optimism among investors.
Bull case
The acquisition by Hanmi Pharmaceutical could provide Aptose with more resources to advance its research and development efforts, potentially leading to new treatment options.
Bear case
Despite the acquisition, Aptose faces significant financial challenges, including a negative return on equity and ongoing losses, which may raise concerns for potential investors.
Recent Price Action
Aptose's stock has remained stable, closing at C$2.40. Over the past week, there has been no change in price, and the stock has also not fluctuated in the last trading day. Year-to-date, the stock has gained 18.81%, reflecting some positive sentiment among investors.
Company News and Developments
Advertisement
Recent headlines highlight the completion of Aptose's acquisition by Hanmi Pharmaceutical, finalized on June 30, 2026. This acquisition may provide the company with additional resources to enhance its clinical development efforts. Additionally, Aptose presented clinical data at the EHA Congress in June, focusing on its TUSCANY Phase 1/2 trial of tuspetinib triplet therapy for acute myeloid leukemia, which could strengthen its position in the healthcare market.
Technical Picture
Currently, Aptose's stock is trading above its 50-day moving average of C$2.25 (+6.4% vs price) and its 200-day moving average of C$2.14 (+12.3% vs price). The stock has a beta of 0.34, suggesting lower volatility compared to the broader market. The 52-week range is between C$1.41 and C$2.59, indicating that the stock is currently trading at 84% of its range. The latest trading volume was 2,945 shares, slightly below the 20-day average volume of 3,425 shares, at a ratio of 0.86x.
Insider Activity
No significant insider trading activity has been reported recently for Aptose, which may indicate stable management and confidence in the companyโs future following the acquisition.
Price Action Summary
Aptose's stock closed at C$2.40, with no change in price over the last day or week. Investors may want to monitor upcoming developments closely as the company continues to pursue its clinical programs and integration with Hanmi Pharmaceutical.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
